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OBJECTIVE—So far it is unclear whether chronic peripheral
hyperinsulinemia per se might contribute to ectopic lipid accu-
mulation and consequently insulin resistance. We investigated
the effects of systemic instead of portal insulin release in type 1
diabetic patients after successful pancreas-kidney transplanta-
tion (PKT) with systemic venous drainage on the intracellular
lipid content in liver and soleus muscle, endogenous glucose
production (EGP), and insulin sensitivity.
RESEARCH DESIGN AND METHODS—In nine PKT patients
and nine matching nondiabetic control subjects, intrahepatocellular
lipids (IHCLs) and intramyocellular lipids (IMCLs) were measured
using
1H nuclear magnetic resonance spectroscopy. Fasting EGP
was measured using D-[6,6-
2H2]glucose tracer dilution. A 3-h 75-g
oral glucose tolerance test (OGTT) allowed us to assess kinetics of
glucose, free fatty acids, insulin, and C-peptide concentrations in
plasma and to calculate the clamp-like index (CLIX) for insulin
sensitivity and the hepatic insulin resistance (HIR) index.
RESULTS—The PKT patients displayed approximately twofold
increased fasting insulin (20  6 vs. 9  3 U/ml; P  0.0002)
compared with that in nondiabetic control subjects and 10%
increased fasting glucose (P  0.02) concentrations, but during
the OGTT areas under the concentration curves of C-peptide
and insulin were similar. IHCL (PKT, 2.9  2.5%; nondiabetic
control subjects, 4.4  6.6%), IMCL (PKT, 1.0  0.4%; nondi-
abetic control subjects, 1.0  0.5%), CLIX (PKT, 8  2;
nondiabetic control subjects, 7  3), HIR (PKT, 25.6  13.2;
nondiabetic control subjects, 35.6  20 [mg  min
1  kg
1] 
[U/ml]), and EGP (PKT, 1.6  0.2; nondiabetic control subjects,
1.7  0.2 mg  min
1  kg
1) were comparable between PKT
patients and nondiabetic control subjects. IHCL was negatively
correlated with CLIX in all participants (r  0.55; P  0.04).
CONCLUSIONS—Despite fasting peripheral hyperinsulinemia
because of systemic venous drainage, type 1 diabetic patients
after PKT show similar IHCL, IMCL, insulin sensitivity, and
fasting EGP in comparison with nondiabetic control subjects.
These results suggest that systemic hyperinsulinemia per se does
not cause ectopic lipid accumulation in liver and skeletal muscle.
Diabetes 59:215–218, 2010
I
nsulin resistance has been linked to lipid accumula-
tion in insulin-responsive tissues such as liver and
skeletal muscle (1–3), but it is not yet clear if ectopic
fat accumulation induces insulin resistance and con-
sequently hyperinsulinemia or whether increased intracel-
lular lipid content is rather the result of long-term
hyperinsulinemia.
Poorly controlled type 1 diabetic patients (4) as well as
insulin-resistant type 2 diabetic subjects and the offspring
of type 2 diabetic subjects displayed increased intracellu-
lar lipid content in skeletal muscle when compared with
healthy individuals (1), whereas well-controlled type 1
diabetic patients exhibited an unchanged intramyocellular
lipid content (5).
Pancreatic transplantation in diabetic subjects with
end-stage renal disease restores insulin secretion and
glucose tolerance (6). Combined pancreas-kidney trans-
plantation (PKT) with systemic venous drainage provides
a human model that allows to study the long-term effects
of systemic instead of portal insulin delivery on glucose
metabolism and intracellular lipid content. It is worth
noting that insulin replacement in diabetic patients is
commonly administered subcutaneously into the systemic
circulation and not through the portal vein (4,7). It is
unclear whether this peripheral route of insulin delivery
has clinically relevant consequences.
We studied whether the systemic route of insulin ap-
pearance could affect intracellular lipid content in liver
and skeletal muscle, as well as endogenous glucose pro-
duction (EGP) in type 1 diabetes after successful pancreas
transplantation.
RESEARCH DESIGN AND METHODS
Following successful combined PKT, nine type 1 diabetic patients were
matched for age and BMI with nine healthy control subjects. The PKT patients
had received whole pancreas grafts with systemic venous anastomosis to the
iliac vein 5.2  1.6 years prior to the study. At the time of examination, the
immunosuppressive regimen in the PKT patients included tacrolimus (n  8)
or sirolimus (n  1) combined with either mycophenolate mofetile (n  6) or
azathioprine (n  2). None was using insulin or any other antihyperglycemic
agent. Five PKT patients received lipid-lowering medication (statins). All
subjects had nondiabetic fasting plasma glucose, glycated A1C 6.5%, and
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the local ethics committee.
An oral glucose tolerance test (OGTT) was performed after an overnight
fast. After the collection of basal samples, participants were given the
standard dose of 75 g glucose in H2O solution (Glukodrink; Roche Diagnos-
tics, Vienna, Austria) within 5 min and remained on bed rest. Venous blood
samples were drawn at 0, 10, 20, 30, 40, 60, 90, 120, 150, and 180 min. Blood
was rapidly centrifuged, and serum and plasma aliquots were stored at 70°C
until further analysis. Insulin sensitivity was estimated by using the clamp-like
index (CLIX) (8).
1H magnetic resonance spectroscopy was used after another 12-h overnight
fast to assess the intramyocellular (IMCL) and intrahepatocellular (IHCL) lipid
content at 3-Tesla (Medspec DBX; Bruker Biospin, Ettlingen, Germany) in the
soleus muscle and the liver. A STEAM sequence (repetition time [TR]  4s ,
echo time [TE]  20 ms, mixing time [TM]  30 ms, 32 averages, voxel volume
[VV]  1.728 ml, and measurement time [TA]  128 s) (9) was used to acquire
muscle spectra. To correct the liver metabolites for their different T2 relax-
ation times, a series of ﬁve breath-hold STEAM experiments (TR  2s ,T M
30 ms, four averages, VV  1.728 ml, and TA  8 s) with varying TE (15, 20,
30, 50, and 70 ms) were performed. Muscle spectra were evaluated using the
linear combination model (9) and were corrected for their T2 relaxation times.
IMCL content was then expressed as the percentage ratio of the (CH2)n group
integral to the sum of the integrals of the (CH2)n group and water resonance
from non–water-suppressed spectra of the same position and VV (10). From
the processed liver spectra, the areas under the lipid (0.4–1.8 ppm) and water
(3.8–5.6 ppm) resonances were integrated at each TE on the console. IHCL
values were calculated from the T2 corrected signals as the percentage ratio
between lipid and the sum of water and lipid integrals. One IMCL and two
IHCL measurements in the PKT patients and one IHCL and two IMCL
measurements in the nondiabetic control subjects could not be completely
ﬁnalized because of the participants’ claustrophobia.
Fasting EGP was assessed from a primed continuous infusion {5 min: 3.6
mg [fasting glucose (mg/dl)/90]; 115 min: 0.036 mg/min  kg body wt} of
D-[6,6-
2H2]glucose (98% enriched) (Cambridge Isotope Laboratories, Andover,
MA). EGP was calculated from blood samples taken after2ho fsteady-state
infusion by dividing D-[6,6-
2H2]glucose infusion rate times tracer enrichment
by the tracer enrichment in plasma and subtracting the tracer infusion rate (3).
A1C and serum concentrations of creatinine, liver transaminases, triglycerides,
total cholesterol, LDL cholesterol, and HDL cholesterol were measured using
routine laboratory methods (www.kimcl.at). Glucose was measured with the
glucose oxidase method (Glucose Analyzer II; Beckman, Fullerton, CA), insulin
and C-peptide by commercially available radioimmunoassays (insulin: Pharma-
cia, Uppsala, Sweden; C-peptide: Cis, Gif-Sur-Yvette, France), and free fatty acids
(FFAs) with a microﬂuorimetric method (Wako, Richmond, VA).
2H2-mole percent excess was assessed in glucose of plasma and infusates
with a 5890 gas chromatograph (Hewlett-Packard, Palo Alto, CA) equipped
with a CP-Sil5 25 m  0.25 mm  0.12 m capillary column (Chrompack,
Middelburg, the Netherlands) and interfaced to a Hewlett-Packard 5971A
mass selective detector, as described elsewhere (3).
Fasting portal insulin concentration was estimated as fasting plasma
insulin times the portal venous-to-systemic insulin gradient, which was 2.4 in
nondiabetic control subjects and 1.0 in the PKT patients (11,12). Hepatic
insulin resistance (HIR) was calculated as the product of EGP times fasting
insulin (13). To account for the different ways of insulin delivery, we modiﬁed
HIR using portal venous insulin concentrations estimated from peripheral
insulin concentrations (11,12). Total areas under concentration curves of
glucose (AUCglucose), insulin (AUCinsulin), and C-peptide (AUCC-peptide) were
calculated with the trapezoidal rule. Dynamic areas under the curve (AUC)
were calculated by subtracting the fasting concentration  180 min from the
total AUC. Data are given as means  SD. Differences between groups were
assessed by the two-tailed Student t test and the 	
2 test for continuous and
categorical variables, respectively; P  0.05 is considered signiﬁcant. Linear
correlations were based on Pearson product moment correlations. All the
continuous variables were normally distributed according to the Kolmogorov-
Smirnov test.
RESULTS
Participants’ characteristics are presented in Table 1. The
two groups did not differ in age, BMI, A1C, serum liver
enzymes, fasting serum triglycerides, FFA, C-peptide, and
HDL cholesterol. The PKT patients had increased serum
creatinine, higher systolic blood pressure, and elevated
fasting insulin but lower total and LDL cholesterol.
During OGTT (Table 1), the fasting glucose and
AUCglucose in the PKT patients were approximately 10%
and 24% higher, respectively, than in the nondiabetic
control subjects, whereas AUCglucose was not different. In
the PKT patients, plasma insulin was twofold elevated at
fasting, while AUC and AUC of insulin and C-peptide
were not different from those of the nondiabetic control
subjects. Fasting C-peptide concentrations were not dif-
ferent between the two groups.
No signiﬁcant differences were found in the comparison
of IHCL and IMCL contents between the PKT patients and
the nondiabetic control subjects (PKT, IHCL 2.9  2.5%
and IMCL 1.0  0.4%; nondiabetic control subjects, IHCL
4.4  6.6% and IMCL 1.0  0.5%). Likewise, fasting EGP,
estimated fasting portal insulin concentration, insulin sen-
sitivity (CLIX), and HIR were not different between the
PKT patients and nondiabetic control subjects (Table 1).
IMCL was negatively correlated with EGP (r  0.67;
P  0.02) and fasting plasma glucose (r  0.56; P 
0.04). IHCL was negatively correlated with CLIX (r 
0.55; P  0.04) and positively correlated with fasting
serum triglycerides (r  0.71; P  0.004). In nondiabetic
control subjects, a positive correlation between IHCL and
IMCL was found (r  0.79; P  0.04). IHCL was positively
correlated with fasting triglycerides (r  0.71; P  0.05),
AUCglucose (r  0.84; P  0.01), and AUCglucose (r  0.81;
P0.02). In PKT patients, IHCL was positively correlated
with AUCinsulin (r  0.86; P  0.02) and AUCinsulin (r 
0.88; P  0.01).
DISCUSSION
Our results show that systemic drainage of the trans-
planted pancreas in type 1 diabetic patients after PKT
leads to elevated peripheral insulin concentrations at
fasting without affecting intracellular lipid content of liver
and soleus muscle. Furthermore, PKT subjects exhibit
fasting EGP and whole-body and hepatic insulin sensitivity
similar to those in healthy, nondiabetic, and age- and
BMI-matched control subjects.
Previous studies in type 1 diabetic patients on subcuta-
neous (systemic) insulin replacement found alterations of
IMCL and IHCL (4,14), which could have resulted from
glucose toxicity given the chronic hyperglycemia (7)
and/or from peripheral hyperinsulinemia. Systemic venous
drainage of PKT allows the investigation of the long-term
effects of peripheral insulin delivery on intracellular lipid
content; to the best of our knowledge, IHCL and IMCL
have never been evaluated in type 1 diabetic patients after
PKT. A study in poorly controlled type 1 diabetic patients
(A1C  8.6%) found increased IMCL of the soleus muscle,
which was directly correlated with A1C values (4),
whereas a study in well-controlled type 1 diabetic patients
(A1C  6.3%) demonstrated unchanged IMCL at fasting
and after sustained hyperinsulinemia (5). In line with that
study, our PKT patients presenting with normal A1C
values and unaltered insulin sensitivity also showed IMCL
similar to that of healthy control subjects, suggesting
beneﬁcial effects of long-term glycemic control.
Evidence exists that peripheral venous insulin replace-
ment for 3 days stimulated skeletal muscle lipid accu-
mulation in type 2 diabetic patients (3); thus, insulin per se
might also affect ectopic lipid accumulation. However, in
nondiabetic humans, hyperinsulinemia only in combina-
tion with elevated circulating lipids did increase IMCL
storage (15). In our PKT patients, unaltered fasting con-
centrations of triglycerides and FFAs would indicate sim-
ilar lipid availability in comparison with nondiabetic
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despite peripheral hyperinsulinemia, our ﬁndings support
the hypothesis that hyperinsulinemia alone does not in-
duce IMCL accumulation.
Insulin resistance is associated with hepatic fat accumu-
lation secondary to increased FFA availability and with
hyperinsulinemia (3). The reported indirect correlation
between IHCL and whole-body insulin sensitivity (3) is
conﬁrmed by our study; however, in contrast to other
studies in type 1 diabetic and type 2 diabetic patients (3,4),
our PKT patients did not differ from healthy, age- and
BMI-matched control subjects in hepatic and peripheral
insulin sensitivity nor in FFA and portal insulin, therefore
exhibiting unaltered IHCL. It is worth noting that the
method used for calculation of insulin sensitivity (CLIX)
(8) uses C-peptide, which is not inﬂuenced by the route of
insulin administration, not being cleared in the liver.
Previous studies have described insulin resistance in pa-
tients after PKT (16,17). However, these studies were
performed in patients taking glucocorticoids, which are
known to deteriorate insulin sensitivity (18,19). Therefore,
the normal insulin sensitivity in our PKT patients conﬁrms
the beneﬁts of glucocorticoid-free immunosuppressive
treatment.
Fasting EGP was similar in PKT patients and nondia-
betic control subjects in spite of systemic insulin delivery,
which is in line with previous studies in pancreas-trans-
planted type 1 diabetic patients with systemic venous
pancreas drainage compared with pancreas-transplanted
patients with portal venous drainage, kidney-transplanted
patients, or healthy control subjects (20,21). On the other
hand, increased fasting EGP and reduced insulin-mediated
EGP suppression was observed in pancreas-transplanted
subjects in comparison with kidney-transplanted patients
and healthy control subjects (22); however, those patients
were on immunsuppressive therapy including glucocorti-
coids (22), while our PKT patients were on a glucocorti-
coid-free medication. It is being debated whether insulin
exerts different effects on EGP when delivered through the
hepatic artery (23) or through the portal vein (24,25) and
which of these routes is more important for the regulation
of EGP. Studies in type 2 diabetic patients, obese, and
healthy humans have shown that short- (3 h) (23) and
long-term (3 days) (3) increases in peripheral insulin levels
cause a pronounced suppression of EGP indicating that
EGP is readily affected by peripheral insulin delivery. In
our study, EGP, estimated fasting portal insulin concen-
tration, and hepatic insulin resistance were unchanged in
PKT, suggesting normal fasting hepatic glucose metabo-
lism despite systemic instead of portal route of insulin
delivery in PKT.
In conclusion, despite displaying fasting peripheral hy-
perinsulinemia but normal lipids, type 1 diabetic patients
after PKT show similar IHCL, IMCL, insulin sensitivity, and
fasting EGP in comparison with nondiabetic control sub-
jects. These results suggest that systemic hyperinsulin-
emia per se does not cause ectopic lipid accumulation in
liver and skeletal muscle.
TABLE 1
Characteristics and experimental parameters of type 1 diabetic patients after PKT and nondiabetic control subjects
PKT patients
Nondiabetic
control subjects P
n (female/male) 4/5 3/6 n.s. (	
2 test)
Age (years) 50  85 3  9 n.s.
Transplant duration (years) 5.2  1.6 — —
BMI (kg/m²)2 6  32 6  2 n.s.
BP systolic/diastolic (mmHg) 136  20/85  11 111  11/76  8 0.005/n.s.
A1C (%) 5.4  0.4 5.6  0.2 n.s.
Creatinine (mg/dl) 1.37  0.29 0.95  0.14 0.002
ASAT (units/l) 23  11 25  6 n.s.
ALAT (units/l) 23  19 26  16 n.s.

GT (units/l) 33  31 31  25 n.s.
Triglycerides (mg/dl) 100  36 134  78 n.s.
Total cholesterol (mg/dl) 168  25 216  31 0.003
HDL cholesterol (mg/dl) 59  13 60  9 n.s.
LDL cholesterol (mg/dl) 92  21 129  26 0.005
OGTT
Fasting plasma glucose (mg/dl) 102  99 2  8 0.02
Fasting plasma insulin (U/ml) 20.1  5.7 9.0  3.1 0.0002
Fasting plasma C-peptide (ng/ml) 2.4  0.6 2.2  1.1 n.s.
Fasting plasma FFA (mol/l) 521  267 522  184 n.s.
AUCglucose (mmol  l
1  min
1) 1,383  225 1,116  171 0.02
AUCglucose (mmol  l
1  min
1) 361  169 200  163 n.s.
AUCinsulin (nmol  l
1  min
1) 77  22 53  44 n.s.
AUCinsulin (nmol  l
1  min
1) 52  18 42  40 n.s.
AUCC-peptide (nmol  l
1  min
1) 399  57 464  242 n.s.
AUCC-peptide (nmol  l
1  min
1) 252  55 332  183 n.s.
EGP, portal venous insulin, and insulin sensitivity
Fasting EGP (mg  min
1  kg
1) 1.6  0.2 1.7  0.2 n.s.
Estimated fasting portal insulin (U/ml) 16.8  8.2 21.7  15.1 n.s.
Insulin sensitivity (CLIX) 8.4  2.2 6.9  2.7 n.s.
HIR (mg  min
1  kg
1)  (U/ml) 25.6  13.2 35.6  20.0 n.s
Data are means  SD unless otherwise indicated. ALAT, alanine aminotransaminases; ASAT, aspartate aminotransaminases; BP, blood
pressure; n.s., not signiﬁcant; 
GT, 
-glutamyl transferase.
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